Cargando…

Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma

PURPOSE: Type 2 diabetes mellitus (T2DM) is among the risk factors for the occurrence and development of cancer. Metformin is a potential anticancer drug. Epidermal growth factor receptor (EGFR) plays an important role in the progression of oral squamous cell carcinoma(OSCC), but the relationship be...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei-Ming, Yang, Si-Si, Shao, Shu-Hui, Nie, Huan-Quan, Zhang, Jing, Su, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864766/
https://www.ncbi.nlm.nih.gov/pubmed/35222283
http://dx.doi.org/10.3389/fendo.2022.828608
_version_ 1784655519396397056
author Wang, Wei-Ming
Yang, Si-Si
Shao, Shu-Hui
Nie, Huan-Quan
Zhang, Jing
Su, Tong
author_facet Wang, Wei-Ming
Yang, Si-Si
Shao, Shu-Hui
Nie, Huan-Quan
Zhang, Jing
Su, Tong
author_sort Wang, Wei-Ming
collection PubMed
description PURPOSE: Type 2 diabetes mellitus (T2DM) is among the risk factors for the occurrence and development of cancer. Metformin is a potential anticancer drug. Epidermal growth factor receptor (EGFR) plays an important role in the progression of oral squamous cell carcinoma(OSCC), but the relationship between metformin and EGFR expression in OSCC remains unclear. METHODS: This study involved the immunohistochemical detection of EGFR expression in cancer tissues of patients with T2DM and OSCC. The patients were divided into groups according to whether they were taking metformin for the treatment of T2DM, and the expression of EGFR in different groups was compared. Correlation analysis between the expression of EGFR and the fluctuation value of fasting blood glucose (FBG) was carried out. Immunohistochemistry was used to detect the expression of EGFR in cancer tissues of patients with recurrent OSCC. These patients had normal blood glucose and took metformin for a long time after the first operation. RESULTS: EGFR expression in T2DM patients with OSCC taking metformin was significantly lower than that in the non-metformin group. FBG fluctuations were positively correlated with the expression of EGFR in the OSCC tissues of the non-metformin group of T2DM patients. In patients with recurrent OSCC with normal blood glucose, metformin remarkably reduced the expression of EGFR in recurrent OSCC tissues. CONCLUSION: Metformin may regulate the expression of EGFR in a way that does not rely on lowering blood glucose. These results may provide further evidence for metformin in the treatment of OSCC.
format Online
Article
Text
id pubmed-8864766
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88647662022-02-24 Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma Wang, Wei-Ming Yang, Si-Si Shao, Shu-Hui Nie, Huan-Quan Zhang, Jing Su, Tong Front Endocrinol (Lausanne) Endocrinology PURPOSE: Type 2 diabetes mellitus (T2DM) is among the risk factors for the occurrence and development of cancer. Metformin is a potential anticancer drug. Epidermal growth factor receptor (EGFR) plays an important role in the progression of oral squamous cell carcinoma(OSCC), but the relationship between metformin and EGFR expression in OSCC remains unclear. METHODS: This study involved the immunohistochemical detection of EGFR expression in cancer tissues of patients with T2DM and OSCC. The patients were divided into groups according to whether they were taking metformin for the treatment of T2DM, and the expression of EGFR in different groups was compared. Correlation analysis between the expression of EGFR and the fluctuation value of fasting blood glucose (FBG) was carried out. Immunohistochemistry was used to detect the expression of EGFR in cancer tissues of patients with recurrent OSCC. These patients had normal blood glucose and took metformin for a long time after the first operation. RESULTS: EGFR expression in T2DM patients with OSCC taking metformin was significantly lower than that in the non-metformin group. FBG fluctuations were positively correlated with the expression of EGFR in the OSCC tissues of the non-metformin group of T2DM patients. In patients with recurrent OSCC with normal blood glucose, metformin remarkably reduced the expression of EGFR in recurrent OSCC tissues. CONCLUSION: Metformin may regulate the expression of EGFR in a way that does not rely on lowering blood glucose. These results may provide further evidence for metformin in the treatment of OSCC. Frontiers Media S.A. 2022-02-09 /pmc/articles/PMC8864766/ /pubmed/35222283 http://dx.doi.org/10.3389/fendo.2022.828608 Text en Copyright © 2022 Wang, Yang, Shao, Nie, Zhang and Su https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wang, Wei-Ming
Yang, Si-Si
Shao, Shu-Hui
Nie, Huan-Quan
Zhang, Jing
Su, Tong
Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma
title Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma
title_full Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma
title_fullStr Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma
title_full_unstemmed Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma
title_short Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma
title_sort metformin downregulates the expression of epidermal growth factor receptor independent of lowering blood glucose in oral squamous cell carcinoma
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864766/
https://www.ncbi.nlm.nih.gov/pubmed/35222283
http://dx.doi.org/10.3389/fendo.2022.828608
work_keys_str_mv AT wangweiming metformindownregulatestheexpressionofepidermalgrowthfactorreceptorindependentofloweringbloodglucoseinoralsquamouscellcarcinoma
AT yangsisi metformindownregulatestheexpressionofepidermalgrowthfactorreceptorindependentofloweringbloodglucoseinoralsquamouscellcarcinoma
AT shaoshuhui metformindownregulatestheexpressionofepidermalgrowthfactorreceptorindependentofloweringbloodglucoseinoralsquamouscellcarcinoma
AT niehuanquan metformindownregulatestheexpressionofepidermalgrowthfactorreceptorindependentofloweringbloodglucoseinoralsquamouscellcarcinoma
AT zhangjing metformindownregulatestheexpressionofepidermalgrowthfactorreceptorindependentofloweringbloodglucoseinoralsquamouscellcarcinoma
AT sutong metformindownregulatestheexpressionofepidermalgrowthfactorreceptorindependentofloweringbloodglucoseinoralsquamouscellcarcinoma